Tumor-associated antigens presented on MHC class I and II of dendritic cell–tumor fusion cells (DC-TFC antigens)

Tumor-associated antigens (TAAs) presented on MHC class I and II of dendritic cell–tumor fusion cells (DC-TFCs) constitute a multifaceted target for cancer immunotherapy. These fusion cells are generated by merging patient-derived dendritic cells with autologous tumor cells, creating a hybrid cell that possesses both the potent co-stimulatory capacity of dendritic cells and the full antigenic profile of the tumor (Koido et al., 2014, PubMed: 24511334). This unique configuration allows for the simultaneous presentation of a broad array of known and unidentified tumor-associated antigens to the immune system (Gong et al., 2000, PubMed: 10835682). Specifically, the fusion cells utilize their endogenous MHC class I and II pathways to activate both CD8+ cytotoxic T lymphocytes and CD4+ helper T cells, respectively (Avigan et al., 2004, PubMed: 15268671). This dual activation is critical for generating a robust and sustained polyclonal anti-tumor immune response capable of overcoming tumor heterogeneity and antigen escape (Rosenblatt et al., 2011, PubMed: 21422443). Clinically, this approach is implemented through autologous vaccines, which have been investigated for the treatment of various cancers, including renal cell carcinoma, melanoma, and glioblastoma. While generally safe, the primary therapeutic challenge involves the potential for inducing autoimmunity against shared antigens and the logistical complexity of manufacturing personalized cell-based therapies.

Other names

Dendritic cell-tumor fusion vaccineDC-tumor cell hybridsFusion cell-based cancer vaccineDC-tumor fusion cell antigensFC-based vaccine

Induction of a polyclonal T-cell response through the simultaneous presentation of a broad repertoire of tumor antigens via MHC class I and II pathways.